{
    "ticker": "ATHS",
    "name": "Athira Pharma, Inc.",
    "description": "Athira Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. Founded in 2019 and headquartered in Seattle, Washington, Athira is focused on addressing conditions such as Alzheimer's disease and other forms of dementia through its proprietary drug candidates. The company's lead product candidate, ATH-1017, is designed to enhance neurotrophic signaling and promote neuronal health, potentially reversing cognitive decline in patients. Athira's research is built on a foundation of extensive scientific investigation into the role of neurotrophic factors in brain health and development. The company is committed to advancing its clinical trials to demonstrate the safety and efficacy of its therapies, aiming to provide new hope for patients and their families affected by debilitating neurological conditions. Athira Pharma is also dedicated to fostering collaborations with research institutions and other stakeholders to further its mission of unlocking new treatment paradigms in the field of neuroscience.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2019",
    "website": "https://www.athirapharma.com",
    "ceo": "Leen Kawas",
    "social_media": {
        "twitter": "https://twitter.com/AthiraPharma",
        "linkedin": "https://www.linkedin.com/company/athira-pharma/"
    },
    "investor_relations": "https://investors.athirapharma.com",
    "key_executives": [
        {
            "name": "Leen Kawas",
            "position": "CEO"
        },
        {
            "name": "Mark A. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ATH-1017"
            ]
        }
    ],
    "seo": {
        "meta_title": "Athira Pharma, Inc. | Innovative Neurodegenerative Disease Therapies",
        "meta_description": "Explore Athira Pharma, Inc., a biotechnology company focused on developing therapies for neurodegenerative diseases like Alzheimer's. Learn about their innovative approaches and clinical trials.",
        "keywords": [
            "Athira Pharma",
            "Neurodegenerative Diseases",
            "Alzheimer's Treatment",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What diseases does Athira Pharma target?",
            "answer": "Athira Pharma focuses on neurodegenerative diseases, particularly Alzheimer's disease and other forms of dementia."
        },
        {
            "question": "Who is the CEO of Athira Pharma?",
            "answer": "Leen Kawas is the CEO of Athira Pharma, Inc."
        },
        {
            "question": "Where is Athira Pharma headquartered?",
            "answer": "Athira Pharma is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What is Athira's lead product candidate?",
            "answer": "Athira's lead product candidate is ATH-1017, aimed at enhancing neurotrophic signaling."
        },
        {
            "question": "When was Athira Pharma founded?",
            "answer": "Athira Pharma was founded in 2019."
        }
    ],
    "competitors": [
        "BIIB",
        "ADBE",
        "AVXL",
        "SAVA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "VRTX"
    ]
}